prexasertib: Clinical Trials

7 trials of prexasertib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 recruiting, 1 terminated. 7 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Completed 4, Recruiting 2, Terminated 1
Phase 11Completed 1

Follow prexasertib: new trials by email Literature Review of prexasertib trials Research Report on prexasertib

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
Gemcitabine, ACR-368 - Head and Neck Squamous Cell Carcinoma
Phase 2RecruitingH. Lee Moffitt Cancer Center and Research Institute432024-09-252025-10-20
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
ACR-368, Gemcitabine, OncoSignature - Endometrial Adenocarcinoma
Phase 2RecruitingAcrivon Therapeutics3502022-08-292026-08-21
A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma
Prexasertib, Irinotecan - Desmoplastic Small Round Cell Tumor, Rhabdomyosarcoma
Phase 1 / Phase 2CompletedMemorial Sloan Kettering Cancer Center212019-09-172025-02-20
A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Prexasertib - Ovarian Cancer
Phase 2CompletedEli Lilly and Company1722018-04-102022-08-19
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
LY2606368 - Advanced Cancers
Phase 2CompletedDana-Farber Cancer Institute272016-10-122022-10-21
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
Prexasertib - Small Cell Lung Cancer
Phase 2CompletedEli Lilly and Company1332016-05-112020-03-17
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
LY2606368 - Ovarian Cancer, Breast Cancer
Phase 2TerminatedNational Cancer Institute (NCI)1112015-01-202022-09-10

Conditions studied

Ovarian Neoplasms (2)  ·  Breast Neoplasms (1)  ·  Desmoplastic Small Round Cell Tumor (1)  ·  Endometrial Neoplasms (1)  ·  Fanconi Anemia (1)  ·  Hereditary Breast and Ovarian Cancer Syndrome (1)  ·  Prostatic Neoplasms (1)  ·  Rhabdomyosarcoma (1)  ·  Small Cell Lung Carcinoma (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Sponsors

Eli Lilly and Company (2)  ·  Acrivon Therapeutics (1)  ·  Dana-Farber Cancer Institute (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  National Cancer Institute (NCI) (1)

Countries

United States (7)  ·  Spain (3)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  South Korea (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Belgium (1)  ·  Greece (1)  ·  Israel (1)  ·  Netherlands (1)  ·  Turkey (Türkiye) (1)  ·  Ukraine (1)

Top investigators

Christine Chung, MD (1)  ·  Emily Slotkin, MD (1)  ·  Geoffrey Shapiro, MD, PhD (1)  ·  Isabelle Ray-Coquard, MD (1)  ·  Jung-Min Lee, M.D. (1)  ·  Panagiotis Konstantinopoulos, MD (1)

Results publications

PMID 34665631, PMID 29361470, PMID 36192237

NIH funding

2015 (1), 2017 (1)